Discovery that specific protein modification important in cancer development

Visualising DNA (blue) and HSP70 (green) during cell division shows that methylated HSP70 associates with DNA (top row), but unmethylated HSP70 is distributed throughout the rest of the cell (bottom row). Credit: http://www.rikenresearch.riken.jp/images/figures/hi_7171.jpg

All proteins are made from chains of amino acids and their functions can be modified by adding small molecules to specific amino acids. One such modification is the addition of a methyl group, which is made of one carbon and three hydrogen atoms, that is attached to the amino acids lysine or arginine. This methylation occurs in many proteins, but its function is unclear.

Heat-shock protein 70 () is one protein that is methylated on a specific lysine amino acid. HSP70 is found in all animals and plays a role in many biochemical processes within cells. Other HSP70 modifications have been directly linked to diseases such as cancer and Parkinson's disease. Now, an international team, including researchers at the RIKEN Advanced Science Institute, Japan, has demonstrated that lysine methylation has similar implications.

Staining HSP70 with fluorescent markers showed that the methylated protein was concentrated in the chromosomes, while the unmethylated protein was spread throughout the cell, outside of the chromosomes. By capturing the methylated protein from cells and identifying the proteins that came with it, the team found an important interaction with an enzyme called Aurora kinase B (AURKB).

"AURKB is an important protein that promotes cell cycle progression and can encourage cancer ," explains co-author Minoru Yoshida. "Indeed, its expression is often deregulated in cancer and its inhibitors have been developed for ."

AURKB activity was enhanced by its interaction with HSP70, and introducing mutant HSP70 into showed that this interaction altered cell growth: HSP70 methylation accelerated cell growth and division. Having found that levels of methylated HSP70 are higher than normal in cultured and tissue from human cancer patients, the team concluded that the modification of the protein is important in the development of cancer.

Despite these findings, Yoshida says there is still much to understand about HSP70 methylation: "It is necessary to do more detailed analyses of why HSP70 is highly methylated in , how it is specifically localized in the nucleus, and how it activates AURKB," he says. But he also thinks that this work provides a new tool in the battle against the disease. "We expect that methylated HSP70 will be a remarkable new cancer diagnosis marker," he says. "As for therapy, not only AURKB inhibitors but also HSP70 methylation inhibitors or a combination of both will be new chemotherapeutic strategies in future."

More information: Cho, H-S., et al. Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. Nature Communications 3, 1072 (2012). www.nature.com/ncomms/journal/v3/n9/full/ncomms2074.html?WT.ec_id=NCOMMS-20120918

add to favorites email to friend print save as pdf

Related Stories

Researchers give mutants another chance

Feb 11, 2009

Researchers at Fox Chase Cancer Center have demonstrated that it might be possible to treat genetic diseases, including some forms of cancer, by "rescuing" the misshapen, useless proteins produced by some mutant genes.

Recommended for you

Unraveling the 'black ribbon' around lung cancer

26 minutes ago

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

Survival hope for melanoma patients thanks to new vaccine

5 hours ago

(Medical Xpress)—University of Adelaide researchers have discovered that a new trial vaccine offers the most promising treatment to date for melanoma that has spread, with increased patient survival rates and improved ability ...

New clinical trial launched for advance lung cancer

9 hours ago

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer – marking a new era of research into personalised medicines ...

User comments